# Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck

> **NCT00581360** · PHASE2 · COMPLETED · sponsor: **University of Pittsburgh** · enrollment: 10 (actual)

## Conditions studied

- Adenoid Cystic Carcinoma

## Interventions

- **DRUG:** doxorubicin and bortezomib

## Key facts

- **NCT ID:** NCT00581360
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2016-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00581360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00581360, "Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT00581360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*